Skip to main content

Breast Cancer

Case Reports, Breast Cancer

Fulvestrant- and Palbociclib-Induced Hepatotoxicity in a Patient with Breast Cancer: A Case Report

Christopher Elder, PharmD, BCOP, Zahava Ohana, PharmD, Waqar Younas, PharmD

Christopher Elder, PharmD, BCOP; Zahava Ohana, PharmD; Waqar Younas, PharmD

Breast Cancer

I-SPY 2: Durvalumab plus Olaparib and Paclitaxel Triplet in High-Risk Breast Cancer “Graduates” to Phase 3 Study

From the Literature, Breast Cancer

Adding Tucatinib to Trastuzumab and Capecitabine Improves Survival in HER2-Positive Metastatic Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

From the Literature, Breast Cancer

Trastuzumab Deruxtecan Shows Durable Antitumor Activity in HER2-Positive Metastatic Breast Cancer

Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Commentary by Robert J. Ignoffo, PharmD, FASHP, FCSHP, FHOPA

Meeting Highlights

Breast Cancer, ESMO Highlights, CDK4/6 Inhibitors

Adding CDK4/6 Inhibitor to Endocrine Therapy Improves Survival in Advanced Breast Cancer: New Standard of Care

Breast Cancer, Multiple Myeloma, Pediatric Cancer, FDA Updates

Vincristine, Racial Disparities in Multiple Myeloma, and HER2 Metastatic Breast Cancer Are in the News

Breast Cancer, FDA Updates

Talzenna (Talazoparib) New PARP Inhibitor Approved for the Treatment of HER2-Negative Advanced Breast Cancer with Germline BRCA Mutation

Lisa A. Raedler, PhD, RPh, Medical Writer

Breast Cancer, FDA Updates

FDA Expands Indication for Kadcyla to Include the Adjuvant Treatment of HER2-Positive Early Breast Cancer

Yvette Florio Lane

Breast Cancer, FDA Updates

FDA Approves First Hormonal-Based Therapy for Men with Advanced or Metastatic Breast Cancer

Yvette Florio Lane

Breast Cancer, FDA Updates

Proposed Landmark Policy Changes to Modernize Mammography and Raise Breast Density Awareness

Yvette Florio Lane

7
8
9
10
11
12

Page 10 of 12
Results 91 - 100 of 114